We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis

By LabMedica International staff writers
Posted on 27 Jan 2025
Print article
Image: The diagnostic sensitivity of the interferon-γ release assay was higher in patients with COPD complicated with active pulmonary tuberculosis (Photo courtesy of Adobe Stock)
Image: The diagnostic sensitivity of the interferon-γ release assay was higher in patients with COPD complicated with active pulmonary tuberculosis (Photo courtesy of Adobe Stock)

Chronic obstructive pulmonary disease (COPD) is a common respiratory condition and a major chronic lung disease that significantly impacts public health and work capacity. Long-term respiratory infections in COPD patients can weaken local respiratory immunity. Due to their immunosuppressive status and frequent corticosteroid use, COPD patients are more vulnerable to developing pulmonary tuberculosis. Conventional diagnostic methods for tuberculosis have shown decreased sensitivity in COPD patients, highlighting the need for more effective diagnostic tests that are easily accessible, well-accepted, simple to administer, and, most importantly, more sensitive in detecting tuberculosis. In a new study, an interferon-γ release assay has demonstrated higher diagnostic sensitivity in COPD patients with pulmonary tuberculosis than other diagnostic methods.

The nested case-control study, conducted between January 2019 and June 2021 at the Fifth Hospital of Shijiazhuang (Hebei, China), involved 123 COPD patients. Thirty-one patients with active pulmonary tuberculosis and COPD formed the observation group (Group A), 31 with nonactive pulmonary tuberculosis and COPD made up the COPD control group (Group B), and 31 patients with active pulmonary tuberculosis without COPD were the non-COPD control group (Group C). Diagnostic tests including interferon-γ release assay, purified protein derivative of tuberculin (PPD) test, anti-tuberculosis antibody test, sputum smear microscopy, and PCR for Mycobacterium tuberculosis were administered to each group. The researchers compared the positive detection rates from all five diagnostic methods.

The results, published in BMC Infectious Diseases, showed that the interferon-γ release assay had higher diagnostic sensitivity for active pulmonary tuberculosis in COPD patients than sputum smear microscopy, PCR, or serum anti-tuberculosis antibody tests. COPD complications did not impact the T-SPOT test results, and higher T-SPOT values indicated a greater likelihood of active tuberculosis. Based on these findings, the researchers recommend that T-SPOT-positive patients, who are clinically considered to have inactive tuberculosis, undergo regular follow-ups to monitor any changes in their condition.

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: Microscopic images showing healthy villi on the left and diseased villi on the right (Photo courtesy of Florian Jaeckle/University of Cambridge)

Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy

Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.